The present observations of elevated LOX levels in an in vivo AD rat model, along with the prevention of AD pathological symptoms by YWCS treatment, corroborates our previous research findings of high LOX levels in the blood of AD patients compared to healthy elderly individuals and shows the neuroprotective effects of the YWCS peptide in AD cell line models. The gene discussed is LOX; the disease is Alzheimer disease.